September 26, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications.
The stock made the NASDAQ top percentage gainers list…
Read More…
Source: https://www.investorideas.com/news/2024/biotech/09261Pasithea-Therapeutics-KTTA.asp